Nestlé to acquire Aimmune Therapeutics in $2.6bn deal
Nestlé Health Science (NHSc), a Nestlé business unit focused on nutritional science, has agreed to acquire biopharmaceutical firm Aimmune Therapeutics for a total enterprise value of around $2.6bn.